Form 8-K Intellia Therapeutics, For: Feb 22
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Form 8-K Intellia Therapeutics, For: Feb 22
February 23, 2024 9:27 AM EST
Evercore ISI analyst Liisa Bayko reiterated an Outperform rating and $70.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "2024 will be a year of execution for NTLA with P3 for NTLA-2001 in ATTR-CM ongoing while preparing P3 for ATTR-PN and HAE. P3 MAGNITUDE study for NTLA-2001 in ATTR-CM kicked off end of last year and will dose the first patient in 1Q. The trial size is slightly greater than that of HELIOS-B (ALNY). We estimate enrollment to complete around year-end 2024 and topline readout in 2H27.... More
February 23, 2024 9:25 AM EST
Citi analyst David Lebowitz reiterated a Neutral rating and $31.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "Following competitor Alnylams HELIOS-B updates (HERE), mgt. remains confident in the event-driven design of NTLA-2001s Ph3 MAGNITUDE trial. While there are no planned... More
February 23, 2024 9:19 AM EST
Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NASDAQ: NTLA) from Buy to Neutral with a price target of $32.00.
The analyst comments "NTLA reported 4Q EPS and reiterated the near-term catalyst path for NTLAs in vivo CRISPR gene-edited therapies, which include: 1) longer-term Ph1 data from NTLA-2001 in ATTR-cardiomyopathy (ATTR-CM) and... More
